Matthias Gromeier, MD

Professor of Neurosurgery
Professor in Molecular Genetics and Microbiology
Professor in Medicine
Member of the Duke Cancer Institute
Campus mail Box 3020 Med Ctr, Durham, NC 27710
Phone (919) 668-6205
Email address grome001@mc.duke.edu

I am a classically trained virologist with a focus on molecular mechanisms of RNA virus pathogenesis. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA metabolism, viral RNA sensing and innate immunity, and cancer immunology and immunotherapy. Basic mechanistic research in my laboratory is supporting an ambitious clinical translational research program with active multi-center clinical trials in several cancer indications. 

Education and Training

  • Postdoctoral Associate, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1996 - 1999
  • Postdoctoral fellow, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1993 - 1996
  • M.D., University of Hamburg (Germany), 1992

Publications

Holl, E., M. Brown, D. Boczkowski, D. Bigner, M. Gromeier, and S. Nair. “POLIO VIRUS THERAPY HAS IMMUNOSTIMULATORY PROPERTIES THAT ARE ACTIVE AGAINST SOLID TUMORS.” In Cytokine, 87:61–62. ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2016.

Scholars@Duke

Mosaheb, M Mubeen, Elena Dobrikova, Michael C. Brown, Christopher Pirozzi, Vidyalakshmi Chandramohan, Eda Holl, Smita Nair, and Matthias Gromeier. “Abstract A032: Using oncolytic polio expressing tumor as a cancer vaccine.” In Antigens and Vaccines. American Association for Cancer Research, 2016. https://doi.org/10.1158/2326-6066.imm2016-a032.

Full Text

Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.

Full Text

Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.

Full Text

Brown, Michael C., and Matthias Gromeier. “Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.” Discovery Medicine 19, no. 106 (May 2015): 359–65.

PMID
26105699
Scholars@Duke

Brown, Michael C., Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, et al. “Oncolytic polio virotherapy of cancer.” Cancer 120, no. 21 (November 1, 2014): 3277–86. https://doi.org/10.1002/cncr.28862.

PMID
24939611
Full Text

Desjardins, A., J. Sampson, K. Peters, G. Vlahovic, S. Threatt, J. Herndon, S. Boulton, et al. “AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.21.

Full Text

Brown, Michael C., Jeffrey D. Bryant, Elena Y. Dobrikova, Mayya Shveygert, Shelton S. Bradrick, Vidyalakshmi Chandramohan, Darell D. Bigner, and Matthias Gromeier. “Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.” J Virol 88, no. 22 (November 2014): 13135–48. https://doi.org/10.1128/JVI.01883-14.

PMID
25187541
Full Text

Pages